期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗在晚期实体瘤治疗中的临床研究进展 被引量：1

The Progress in Bevacizumab Clinical Trial in the Treatment for Advanced Solid Tumor
原文传递
导出
摘要 贝伐单抗是一种针对血管内皮因子的重组人源化单克隆抗体,可阻止或减弱VEGF与其受体结合,从而抑制其生物学活性,减少肿瘤新生血管形成,达到抑制肿瘤生长的目的。文章就近年来贝伐单抗的相关基础与临床研究,以及在各种实体瘤治疗中的研究进展作一综述。
作者 柏和 罗显峰 宋纯 樊文竹
机构地区 辽宁省肿瘤医院
出处 《中国肿瘤》 CAS 2010年第12期824-827,共4页 China Cancer
关键词 贝伐单抗 化疗 实体瘤 癌
分类号 R73-36 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Kerbel RS. Tumor angiogensis [J]. New Engl J Med, 2008, 238: 2038- 2049.
  • 2Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer [J]. Curr Opin Genet Dev, 2005, 15:102-111.
  • 3Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350:2335-2342.
  • 4Sahz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase Ⅲ study [J]. J Clin Oncol, 2008, 26:2013-2019.
  • 5G.P. Stathopoulos C, Batziou D, Trafalis J, et al. Treatment of Colorectal Cancer with and without Bevacizumab: A Phase Ⅲ Study [J]. Oncology, 2010, 78: 376-381.
  • 6Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, Phase Ⅲ study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [J]. J Clin Oncol, 2008, 26: Abstract LBA1011.
  • 7Robert N J, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, Phase Ⅲ trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER-2- negative locally recurrent or metastatic breast cancer (MBC)[J]. J Clin Oncol, 2009, 27: Abstract 1005.
  • 8Reck M, yon Pawel J, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL[J]. J Clin Oncol, 2009, 27:1227- 1234.
  • 9Manegold C, yon Pawel J, Zatloukal P, et al. B017704 (AVAIL): A phase Ⅲ randomised study of first-line beva- cizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non- small cell lung cancer (NSCLC)[J]. Ann Oncol, 2008, 19: LBA1.
  • 10Pavlakis N, Crino L, Dansin E, et al. M019390 (SaiL) Study Group: safety of bevacizumab (Bv)-based therapy as first- line treatment of eligible non-small cell lung cancer (NSCLC) patients (pts)[J]. Ann Oncol, 2008, 19: 232PD.

同被引文献8

  • 1Smith BR,Stabile BE.Extreme aggressiveness and lethalityof gastric adenocarcinoma in the very young[J].Arch Surg,2009,144(2):506-510.
  • 2Hicklin DJ,Ellis LM.Role of the vascular endothelial growthfactor pathway in tumor growth and angiogenesis[J].ClinOncol,2005,23(5):1011-1027.
  • 3Chowdury MW,Scaramuzzi RJ,Wheeler-Jones CP,et al.Theexpression of angiogenic growth factors and their receptors inovarian follicles throughout the estrous cycle in the ewe[J].Theriogenology,2010,73(7):856-872.
  • 4Vaziri SA,Kim J,Ganapathi MK,et al.Vascular endothelialgrowth factor polymorphisms:role in response and toxicity oftyrosine kinase inhibitors[J].Curr Oncol Rep,2010,12(2):102-108.
  • 5Idogawa M,Sasaki Y,Suzuki H,et al.A single recombinantadenovirus expressing p53and p21-targeting artificialmicroRNAs efficiently induces apoptosis in human cancercells[J].Clin Cancer Res,2009,15(11):3725-3732.
  • 6Mittmann N,Auh J,Tu D,et al.Prospective cost-effectiveness analysis of cetuximab in metastatic colorectalcancer:evaluation of National Cancer Institute of CanadaClinical Trials Group CO.17Trial[J].J Natl Cancer lnst,2009,101(17):1182-1192.
  • 7仲召阳,张沁宏,卿毅,李梦侠,李增鹏,王东.APE1 siRNA重组腺病毒增强贝伐单抗对移植骨肉瘤的治疗作用[J].中国肿瘤生物治疗杂志,2009,16(4):331-335. 被引量：3
  • 8李扬,胡欣,程刚,聂颖兰,赵贇博,伍建宇,武晓楠,丁丽,李琳,宋葵,戴雪松,李可欣,刘蕾,戚川.贝伐单抗在中国晚期恶性肿瘤受试者中的药动学研究[J].中国药学杂志,2010,45(22):1749-1752. 被引量：3

引证文献1

中国肿瘤
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部